07/01/2014 - 12:50pm

Actavis and Forest Labs. on Monday announced that the U.S. Federal Trade Commission has voted to approve Actavis' proposed acquisition of Forest.

06/24/2014 - 8:14am

As Walgreens carefully considers how to best execute the second step of its acquisition of Alliance Boots, Walgreens on Tuesday relayed its progress in improving its domestic business, including the company's success in winning the prescription business of high-value seniors and the pending national launch of its Boots No7 beauty brand.

06/20/2014 - 9:37am

Merck announced on Friday that it is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals. On June 9, Merck announced its intent to acquire Idenix.

06/19/2014 - 10:26am

More than 1-in-4 Rite Aid locations now reflect the latest in healthcare retailing — the company's Wellness store format, the concept that serves as a cornerstone to Rite Aid's overall health-and-wellness solution, John Standley, Rite Aid chairman and CEO, told analysts Thursday morning.

06/19/2014 - 9:46am

Starting off the year with a strong momentum, Kroger posted a 9% increase in first-quarter sales, which marked the first period that includes Harris Teeter in the statement of operations. Based on its strong quarter, the company has raised its fiscal 2014 guidance.

06/16/2014 - 1:35pm

Allergan issued a statement Monday, reiterating the company's concern for what it calls Valeant Pharmaceuticals’ “unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operational excellence,” the company stated.

06/13/2014 - 9:48am

99 Cents Only Stores on Friday posted sales of $477.9 million for the first quarter ended May 2, representing a sales lift of 7.3%.

06/12/2014 - 1:24pm

Consumer spending rose 0.3% in May, marking four consecutive months of rising U.S. retail sales.

06/09/2014 - 12:25pm

Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.